Figure 2. Catumaxomab induces a mobilization of CD8⁺ T cells and NK cells and an activation of CD4⁺ and CD8⁺ T cells. (A) The catumaxomab-induced redistribution of lymphocytes subsets was analyzed in patients with gastric cancer (n = 6) shortly before surgery was performed (Pre), on day 17 after gastrectomy following infusion of the final dose of catumaxomab (Post), and 4 weeks after the last catumaxomab application (EOT) using four-color flow cytometry. Analysis was performed using a combination of a morphological lymphocyte gate and gates for CD8⁺ T cells (CD3⁺CD8⁺) and NK cells (CD3^-CD56⁺), respectively. Logarithmically plotted values depict individual changes during treatment in comparison to results at baseline (Pre). (B) Fold changes in percentages of CD4⁺ and CD8⁺ T cells expressing activation markers CD69 and HLA-DR, respectively, were evaluated for the same patients and time points. Each patient (GC-01 to GC-06) is indicated by a separate symbol as given below the figure.